MPN

David Alexander, from the MPN Education Foundation, discusses MPNs as a chronic disease and learning how to live a new normal.
 

Dr. Ruben Mesa, from the MPN Education Foundation, discusses various treatment options for myeloproliferative neoplasms, and highlights how advances in research can help patients with the disease and beyond.
 

Dr. Ruben Mesa, from the MPN Education Foundation, discusses MPN diagnoses, and why it is key for patients and caregivers to understand the disease to have improved conversations with physicians.
 

Dr. Ruben Mesa, from the MPN Education Foundation, discusses the three types of myeloproliferative neoplasms and how they differ from one another.
 

Individuals living with myeloproliferative neoplasm (MPN) often face a markedly different experience compared to those patients with other types of blood cancer. Unfortunately, there tends to be less known about this population due to its smaller size. But tools like the recently published “Blood Cancer in America” 2020 survey aim to help highlight the disparities faced by the MPN community and give a voice to those who may feel unheard.

MPN Hero Dr. Irum Khan discusses how education events for patients with cancer are helpful to both the patient and the clinician.
 

In this special edition of the “CURE Talks Cancer” podcast, we teamed up with our sister publication “OncLive on Air” to speak with a patient-doctor duo on myeloproliferative neoplasms.
 

Jeffrey Glen Jones – an American illustrator who started doing comic books about 25 years ago –  is using his creative talents to illustrate the stories of those impacted by MPNs, as part of a campaign called Rare Reflections: MPNs Unmasked.
 

In the 2020 Hematology 1 special edition of CURE magazine, we highlight what it means to be an everyday hero by living with MPN or helping patients with the disease cope with it.

Survival among patients with myelofibrosis who discontinued treatment with Jakafi appeared to have poorer survival, which was most prominent in those who stopped during the blast phase of treatment.